We have located links that may give you full text access.
The level of evidence of medical marijuana use for treating disabilities: a scoping review.
Disability and Rehabilitation 2018 November 21
PURPOSE: Twenty-nine states have bypassed federal regulations by legalizing marijuana (MJ) either medicinally, recreationally or both. The FDA states that there is no empirical evidence that MJ is effective to treat these disorders. With over a billion individuals living with a disability across the globe, it is crucial to fully research the efficaciousness and safety of medical MJ to treat this population. The purpose to present the results of a scoping review of studies focused on the levels of evidence currently available on medical MJ's efficacy in treatment across a large range of disabilities.
METHODS: Databases were searched for research articles on the current level of evidence to support medical MJ use among people with disabilities.
RESULTS: Forty-one peer reviewed articles met the inclusion criteria. Articles focused on attention deficit hyperactivity disorder, post-traumatic stress disorder, depression, schizophrenia, spinal cord injury, multiple sclerosis/movement disorders, fibromyalgia, epilepsy, with some that focused on multiple disabilities.
CONCLUSIONS: The level of evidence for the use of medical MJ among people with disabilities varies greatly, and has a clear lack of methodologically sound studies. Overall, medical MJ does not improve the level of functioning, but it may improve the overall quality of life for people with disabilities. Implications for Rehabilitation Epilepsy can be a disabling chronic disorder which not only impacts physically but can restricts quality of life. Quality of life is diminished even more with treatment resistant epilepsy. Chronic pain is the leading cause of disability and is the most common cause of long-term disability. There is sufficient evidence that medical marijuana is effective in treating epileptic seizures and chronic pain. Medical marijuana may improve the level of functioning and quality of life for individuals with certain disabilities.
METHODS: Databases were searched for research articles on the current level of evidence to support medical MJ use among people with disabilities.
RESULTS: Forty-one peer reviewed articles met the inclusion criteria. Articles focused on attention deficit hyperactivity disorder, post-traumatic stress disorder, depression, schizophrenia, spinal cord injury, multiple sclerosis/movement disorders, fibromyalgia, epilepsy, with some that focused on multiple disabilities.
CONCLUSIONS: The level of evidence for the use of medical MJ among people with disabilities varies greatly, and has a clear lack of methodologically sound studies. Overall, medical MJ does not improve the level of functioning, but it may improve the overall quality of life for people with disabilities. Implications for Rehabilitation Epilepsy can be a disabling chronic disorder which not only impacts physically but can restricts quality of life. Quality of life is diminished even more with treatment resistant epilepsy. Chronic pain is the leading cause of disability and is the most common cause of long-term disability. There is sufficient evidence that medical marijuana is effective in treating epileptic seizures and chronic pain. Medical marijuana may improve the level of functioning and quality of life for individuals with certain disabilities.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app